- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Celyad SA (CYAD)
Celyad SA stock price live, this page displays EBR CYAD stock exchange data. View the CYAD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Celyad SA real time stock price chart below.
What Is the Celyad SA Stock Price Today?
The Celyad SA stock price today is 0.24.
What Is the Stock Symbol for Celyad SA?
The stock symbol for Celyad SA is ""CYAD.""
What Stock Exchange Does Celyad SA Trade On?
Celyad SA is listed and trades on the Brussels stock exchange.
Is Celyad SA a Good Stock to Buy?
Determining whether Celyad SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYAD quote. (ISIN: BE0974260896)
What Is the Celyad SA Stock Price Today?
The Celyad SA stock price today is 0.24.
What Is the Stock Symbol for Celyad SA?
The stock symbol for Celyad SA is ""CYAD.""
What Stock Exchange Does Celyad SA Trade On?
Celyad SA is listed and trades on the Brussels stock exchange.
Is Celyad SA a Good Stock to Buy?
Determining whether Celyad SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYAD quote. (ISIN: BE0974260896)
0.24
-0.01(-4.00%)
Closed·
Fair Value
An estimate of a Celyad's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.23
0.25
52 wk Range
0.22
1.22
Unusual trading volume
1/2
Fair Value
An estimate of a Celyad's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.230.25
52 wk Range
0.221.22
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
CYAD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Celyad's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Celyad SA Company Profile
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Compare CYAD to Peers and Sector
Metrics to compare | CYAD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYADPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −1.9x | −0.7x | |
PEG Ratio | −0.06 | 0.01 | 0.00 | |
Price/Book | −3.5x | 1.0x | 2.6x | |
Price / LTM Sales | 57.8x | 26.5x | 3.4x | |
Upside (Analyst Target) | - | 20.1% | 39.1% | |
Fair Value Upside | Unlock | 0.1% | 5.4% | Unlock |
Earnings
Latest Release
Sep 25, 2025
EPS / Forecast
-0.04 / --
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Celyad Trade On?
Celyad is listed and trades on the Brussels Stock Exchange stock exchange.
What Is the Stock Symbol for Celyad?
The stock symbol for Celyad is "CYAD."
What Is the Celyad Market Cap?
As of today, Celyad market cap is 10.74M.
What Is Celyad's Earnings Per Share (TTM)?
The Celyad EPS (TTM) is -0.16.
When Is the Next Celyad Earnings Date?
Celyad will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is CYAD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Celyad Stock Split?
Celyad has split 0 times.
How Many Employees Does Celyad Have?
Celyad has 18 employees.
What is the current trading status of Celyad (CYAD)?
As of 19 Oct 2025, Celyad (CYAD) is trading at a price of 0.24, with a previous close of 0.25. The stock has fluctuated within a day range of 0.23 to 0.25, while its 52-week range spans from 0.22 to 1.22.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.